ALX Oncology
Powering the next era of cancer treatment
- Headquarters
- South San Francisco, California
- Business Model
- B2B
About
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, with a focus on immuno-oncology. The company's lead program, evorpacept, is designed to block the CD47 'don't eat me' signal, enabling the immune system to recognize and destroy cancer cells across multiple tumor types. Headquartered in South San Francisco, California, ALX Oncology went public in July 2020 and is led by a team of experienced oncology drug developers committed to delivering next-generation breakthrough cancer treatments.
Summary
ALX Oncology is an Oncology company based in South San Francisco, United States.
Similar Companies
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...
Avenzo is a San Diego, CA-based biopharma company to in-license and develop the next generation o...
Clinical-stage biopharma developing dual-action biologics that combine targeted therapy and immun...
Novel bicyclic peptides and drug conjugates for cancer
Clinical-stage biopharmaceutical company founded in 2015 developing best-in-class cancer therapeu...
Pathos is an AI-enabled biotechnology company focused on re-engineering drug development.